
A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation

A Phase III Study of Marimastat in Patients with Small Cell Lung Cancer Following a Response to First Line Chemotherapy

A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer

This Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer

Phase III Study of Tomudex and Cisplatin versus Cisplatin in Malignant Pleural Mesothelioma

A Phase II/III Double Blind Randomized Trial of BMS-275291 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy For the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase III Prospective Randomized Double Blind Placebo Controlled Trial of the Epidermal Growth Factor Receptor Antagonist ZD1839 (IRESSA) in Completely Resected Stage 1B, II, and IIIA Non-Small Cell Lung Cancer

A Phase II Study of ZD6474 or Placebo in Small Cell Lung Cancer Patients Who Have Complete or Partial Response to Induction Chemotherapy Plus Radiation Therapy

A Randomized Placebo Controlled Study of OSI-774 (Tarceva) in Patients with Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB(T2N0), II(T1-2N1, T3N0) and Selected IIIA(T3N1) Non-Small Cell Lung Cancer.

This Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer

This Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer

A Phase II/III Double Blind Randomized Trial of AZD2171 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease

Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status

A Double Blind Randomized Trial of Cediranib versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer
Inventory
Show Tissue Samples
Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
LUNG | BR10 | 532 | 451 | 454 | 471 |
LUNG | BR12 | 555 | 54 | 4 | 58 |
LUNG | BR15 | 56 | 10 | 2 | 12 |
LUNG | BR15C | 47 | 3 | 3 | 6 |
LUNG | BR17 | 20 | 1 | 1 | 2 |
LUNG | BR18 | 774 | 165 | 236 | 262 |
LUNG | BR19 | 503 | 376 | 414 | 425 |
LUNG | BR20 | 107 | 53 | 7 | 55 |
LUNG | BR21 | 731 | 270 | 432 | 438 |
LUNG | BR22 | 6 | 0 | 1 | 1 |
LUNG | BR22C | 5 | 0 | 3 | 3 |
LUNG | BR23C | 8 | 0 | 2 | 2 |
LUNG | BR24 | 296 | 53 | 118 | 145 |
LUNG | BR26 | 720 | 601 | 672 | 690 |
LUNG | BR28 | 41 | 1 | 1 | 1 |
LUNG | BR29 | 306 | 101 | 79 | 159 |
LUNG | BR31 | 1834 | 326 | 60 | 330 |
LUNG | BR34 | 301 | 172 | 282 | 295 |
LUNG | BR36 | Open Trial | 8 | 0 | 8 |
(Core size is 0.6 mm)
Show
Fluid SamplesDisease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
LUNG | BR10 | 532 | 3 | 331 |
LUNG | BR12 | 555 | 0 | 0 |
LUNG | BR15 | 56 | 0 | 0 |
LUNG | BR15C | 47 | 0 | 0 |
LUNG | BR17 | 20 | 0 | 0 |
LUNG | BR18 | 774 | 2 | 60 |
LUNG | BR19 | 503 | 9 | 342 |
LUNG | BR20 | 107 | 1 | 1 |
LUNG | BR21 | 731 | 0 | 0 |
LUNG | BR22 | 6 | 0 | 0 |
LUNG | BR22C | 5 | 0 | 0 |
LUNG | BR23C | 8 | 0 | 0 |
LUNG | BR24 | 296 | 0 | 0 |
LUNG | BR26 | 720 | 2 | 52 |
LUNG | BR28 | 41 | 1 | 1 |
LUNG | BR29 | 306 | 1 | 9 |
LUNG | BR31 | 1834 | 1 | 30 |
LUNG | BR34 | 301 | 1 | 6 |
LUNG | BR36 | Open Trial | 0 | 0 |
Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
LUNG | BR10 | 532 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
LUNG | BR12 | 555 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR15 | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR15C | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR17 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR18 | 774 | 0 | 0 | 0 | 0 | 20 | 439 | 0 | 0 |
LUNG | BR19 | 503 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR20 | 107 | 0 | 0 | 0 | 1 | 99 | 0 | 93 | 0 |
LUNG | BR21 | 731 | 0 | 0 | 0 | 0 | 728 | 1 | 0 | 0 |
LUNG | BR22 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR22C | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR23C | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LUNG | BR24 | 296 | 234 | 0 | 234 | 235 | 249 | 254 | 0 | 0 |
LUNG | BR26 | 720 | 706 | 0 | 2 | 0 | 710 | 710 | 0 | 0 |
LUNG | BR28 | 41 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 0 |
LUNG | BR29 | 306 | 58 | 0 | 16 | 16 | 61 | 61 | 0 | 0 |
LUNG | BR31 | 1834 | 970 | 0 | 0 | 0 | 865 | 971 | 0 | 0 |
LUNG | BR34 | 301 | 299 | 0 | 0 | 0 | 299 | 298 | 0 | 0 |
LUNG | BR36 | Open Trial | 12 | 0 | 0 | 0 | 12 | 0 | 0 | 0 |